ZFIN ID: ZDB-FISH-150901-16688
Fish name: tp53zdf1/zdf1
Genotype: tp53zdf1/zdf1
Targeting Reagent: none
HUMAN DISEASE MODELED by tp53zdf1/zdf1
No data available
GENE EXPRESSION
Gene expression in tp53zdf1/zdf1
RNA expression
Expressed Gene Structure Conditions Figures
apex1 control Fig. 6 from Pei et al., 2011
baxa standard conditions Fig. 4 with image from Chua et al., 2015
gamma ray Fig. 4 with image from Chua et al., 2015
bbc3 standard conditions Fig. 4 with image from Chua et al., 2015
gamma ray Fig. 4 with image from Chua et al., 2015
bnip3lb control Fig. 10 from Feng et al., 2011
hypoxia Fig. 10Fig. 11 from Feng et al., 2011
cdkn1a standard conditions Fig. 3 with image from Song et al., 2016
Fig. 4 with image from Chua et al., 2015
Fig. 4 with image from EspĂ­n et al., 2013
Fig. 5 with image from Santoriello et al., 2010
radiation Fig. 4 with image from Chua et al., 2015
Fig. 5 with image from Santoriello et al., 2010
creb1a control Fig. 6 from Pei et al., 2011
crestin standard conditions Fig. 8 with image from Li et al., 2014
en2a control Fig. 2 with image from Dworkin et al., 2012
etv5b control Fig. 1 with image from Terriente et al., 2012
fgf20a control Fig. 1 with imageFig. 2 with imageFig. 3 with imageFig. 4 with image from Terriente et al., 2012
gadd45aa control Fig. 3 with image from Song et al., 2016
her9 control Fig. 2 with image from Terriente et al., 2012
hoxb1b control Fig. 2 from Ma et al., 2015
mdm2 standard conditions Fig. 4 with image from Chua et al., 2015
Fig. 5 with image from Santoriello et al., 2010
radiation Fig. 4 with image from Chua et al., 2015
Fig. 5 with image from Santoriello et al., 2010
mir200a standard conditions Fig. 6 from Xiong et al., 2018
mir200b standard conditions Fig. 6 from Xiong et al., 2018
mir429 standard conditions Fig. 6 from Xiong et al., 2018
chemical treatment by environment: estrogen Fig. 6 from Xiong et al., 2018
mpx control Fig. 2 from Bolli et al., 2010
myb standard conditions Fig. 6 with image from Wei et al., 2016
Fig. S13 with image from Jia et al., 2015
myl7 standard conditions Fig. 4 from Yan et al., 2013
neurog1 control Fig. 5 with image from Terriente et al., 2012
pax2a control Fig. 2 with image from Dworkin et al., 2012
pes control Fig. 7 with image from Provost et al., 2012
rag1 standard conditions Fig. 6 with image from Wei et al., 2016
rfng control Fig. 1 with image from Terriente et al., 2012
rpl3 control Fig. 5 with image from Provost et al., 2012
rrm2b control Fig. 3 with image from Song et al., 2016
sema3fb control Fig. 2 with image from Terriente et al., 2012
sema3gb control Fig. 2 with image from Terriente et al., 2012
sox9b standard conditions Fig. 8 with image from Li et al., 2014
sox10 standard conditions Fig. 7 with image from Shin et al., 2012
tp53 standard conditions Fig. 4 with imageFig. 6 with imageFig. 7 with image from Chua et al., 2015
Fig. 7 with image from Heijnen et al., 2014
gamma ray Fig. 4 with image from Chua et al., 2015
Protein expression
Antibody Antigen Genes Structure Conditions Figures
Ab10-tp53 control Fig. 1 from Gong et al., 2015
Ab3-ampka standard conditions Fig. S9 with image from Kim et al., 2013
Ab1-elavl standard conditions Fig. 7 with image from Shin et al., 2012
Fig. 5 with image from Terriente et al., 2012
Ab19-h3 standard conditions Fig. 7 with image from Shin et al., 2012
Ab10-tp53 gamma ray Fig. 1 from Gong et al., 2015
Ab2-akt standard conditions Fig. 4 with image from Kim et al., 2013
Ab3-tsc2 standard conditions Fig. 4 with imageFig. S3 with image from Kim et al., 2013
Ab3-gfap standard conditions Fig. 7 with image from Shin et al., 2012
Ab7-akt standard conditions Fig. 4 with imageFig. S5 with image from Kim et al., 2013
Ab1-epas1 standard conditions Fig. 5 with imageFig. S6 with image from Kim et al., 2013
Ab1-casp3 chemical treatment: pharmaceutical Fig. 2 with image from Toruno et al., 2014
ab1-epha4a control Fig. 1 with imageFig. 2 with imageFig. 3 with imageFig. 4 with imageFig. 5 with image from Terriente et al., 2012
Ab1-casp3 control Fig. 2 with image from Toruno et al., 2014
Ab1-hif1a standard conditions Fig. 5 with image from Kim et al., 2013
Ab1-rps6 standard conditions Fig. 1 with imageFig. 2 with imageFig. S1 with image from Kim et al., 2013
Ab2-syp standard conditions Fig. 7 with image from Shin et al., 2012
Ab2-vegfc standard conditions Fig. 5 with imageFig. S7 with image from Kim et al., 2013
Ab1-eif4ebp1 standard conditions Fig. 1 with image from Kim et al., 2013
Ab1-casp3 radiation Fig. 2 with image from Toruno et al., 2014
Ab1-apex1 apex1 control Fig. 6 from Pei et al., 2011
Ab1-sox10 sox10 standard conditions Fig. 7 with image from Shin et al., 2012
Ab2-tp53 tp53 standard conditions Fig. 6 with imageFig. 7 with image from Chua et al., 2015
Reporter gene expression No data available
PHENOTYPE
Phenotype in tp53zdf1/zdf1
Phenotype Conditions Figures
angiogenesis increased occurrence, abnormal standard conditions Fig. 5 with image from Kim et al., 2013
apoptotic process increased rate, abnormal hypoxia Fig. 12 from Feng et al., 2011
caudal fin apoptotic process increased process quality, abnormal chemical treatment: pharmaceutical Fig. 2 with image from Toruno et al., 2014
cellular response to ionizing radiation decreased process quality, abnormal radiation Fig. 2 with image from Toruno et al., 2014
double-strand break repair via homologous recombination increased frequency, abnormal standard conditions Fig. 1 from Gong et al., 2015
double-strand break repair via nonhomologous end joining increased frequency, abnormal standard conditions Fig. 1 from Gong et al., 2015
double-strand break repair via single-strand annealing increased frequency, abnormal standard conditions Fig. 1 from Gong et al., 2015
embryonic hemopoiesis process quality, normal control Fig. S7 with image from Novikov et al., 2013
heart morphology, normal control Fig. S7 with image from Novikov et al., 2013
heart tube decreased length, normal standard conditions Fig. 4 from Yan et al., 2013
neuron apoptotic process process quality, normal standard conditions Fig. 1 from Ko et al., 2011
nucleate erythrocyte normal amount, normal standard conditions Fig. 3 with image from Zhang et al., 2012
nucleate erythrocyte hemoglobin complex amount, normal control Fig. 1 with image from Narla et al., 2014
oocyte present, normal standard conditions Fig. 7 with image from Rodriguez-Mari et al., 2011
peripheral nervous system neoplastic, malignant, abnormal standard conditions Fig. 4 with image from Shive et al., 2010
peripheral nervous system neurofibrosarcoma increased amount, abnormal standard conditions Fig. 4 with image from Zhang et al., 2010
sperm increased cellular motility, abnormal chemical treatment by environment: estrogen Fig. 6 from Xiong et al., 2018
sperm increased cellular motility, abnormal standard conditions Fig. 6 from Xiong et al., 2018
sperm increased velocity, abnormal chemical treatment by environment: estrogen Fig. 6 from Xiong et al., 2018
sperm increased velocity, abnormal standard conditions Fig. 6 from Xiong et al., 2018
testis mir200b expression decreased amount, abnormal standard conditions Fig. 6 from Xiong et al., 2018
testis mir200a expression decreased amount, abnormal standard conditions Fig. 6 from Xiong et al., 2018
testis mir429 expression decreased amount, abnormal chemical treatment by environment: estrogen Fig. 6 from Xiong et al., 2018
testis mir429 expression decreased amount, abnormal standard conditions Fig. 6 from Xiong et al., 2018
trunk sarcoma present, abnormal standard conditions Fig. 1 with image from Kim et al., 2013
whole organism morphology, normal control Fig. 2 with image from Dworkin et al., 2012
whole organism neoplastic, abnormal standard conditions Fig. 1 with image from Park et al., 2016
whole organism apoptotic process decreased frequency, abnormal gamma ray Fig. 8 from Ando et al., 2017
whole organism apoptotic process increased frequency, exacerbated gamma ray, chemical treatment: Goe 6976 Fig. 8 from Ando et al., 2017
whole organism neoplasm increased occurrence, abnormal standard conditions Fig. 1 with image from Park et al., 2016

CITATIONS  (99)